Repository hosted by TU Delft Library

Home · Contact · About · Disclaimer ·

Inhibition of complement component C3 reduces vein graft atherosclerosis in apolipoprotein E3-Leiden transgenic mice

Publication files not online:

Author: Schepers, A. · Vries, M.R. de · Leuven, C.J. van · Grimbergen, J.M. · Holers, V.M. · Daha, M.R. · Bockel, J.H. van · Quax, P.H.A.
Institution: TNO Kwaliteit van Leven
Source:Circulation, 25, 114, 2831-2838
Identifier: 239633
doi: doi10.1161/CIRCULATIONAHA.106.619502
Keywords: Biology · Biomedical Research · Atherosclerosis · Bypass · Complement system proteins · Immunology · CD59 antigen · cobrotoxin · complement component C1q · complement component C3 · complement component C9 · complement inhibitor · complement receptor related protein immunoglobulin G1 fusion protein · messenger RNA · regulator protein · animal experiment · animal model · animal tissue · antiinflammatory activity · apoptosis · artery intima proliferation · atherosclerosis · cell proliferation · common carotid artery · complement activation · complement inhibition · controlled study · drug effect · drug efficacy · experimental model · gene expression · immunohistochemistry · inflammatory cell · male · monocyte · mouse · neutrophil chemotaxis · nonhuman · priority journal · quantitative analysis · RNA analysis · T lymphocyte · treatment outcome · vein graft disease · Animals · Apolipoprotein E3 · Atherosclerosis · Complement C3 · Diet, Atherogenic · Disease Models, Animal · Humans · Mice · Mice, Transgenic · Transplantation, Isogeneic · Venae Cavae


BACKGROUND - Venous bypass grafts may fail because of development of intimal hyperplasia and accelerated atherosclerosis. Inflammation plays a major role in these processes. Complement is an important part of the immune system and participates in the regulation of inflammation. The exact role of complement in the process of accelerated atherosclerosis of vein grafts has not yet been explored, however. METHODS AND RESULTS - To assess the role of complement in the development of vein graft atherosclerosis, a mouse model, in which a venous interposition was placed in the common carotid artery, was used. In this model, vein graft thickening appeared within 4 weeks. The expression of complement components was studied with the use of immunohistochemistry on sections of the thickened vein graft. C1q, C3, C9, and the regulatory proteins CD59 and complement receptor-related gene y could be detected in the lesions 4 weeks after surgery. Quantitative mRNA analysis for C1q, C3, CD59, and complement receptor-related gene y revealed expression of these molecules in the thickened vein graft, whereas C9 did not show local mRNA expression. Furthermore, interference with C3 activation with complement receptor-related gene y-Ig was associated with reduced vein graft thickening, reduced C3 and C9 deposition, and reduced inflammation as assessed by analysis of influx of inflammatory cells, such as leukocytes, T cells, and monocytes. In addition, changes in apoptosis and proliferation were observed. When C3 was inhibited by cobra venom factor, a similar reduction in vein graft thickening was observed. CONCLUSIONS - The complement cascade is involved in vein graft thickening and may be a target for therapy in vein graft failure disease. © 2006 American Heart Association, Inc. Chemicals / CAS: cobrotoxin, 12584-83-7, 8001-03-4; complement component C1q, 80295-33-6; complement component C3, 80295-41-6; apolipoprotein E3 (Leidein); Apolipoprotein E3; Complement C3